Search our Database of Scientific Publications and Authors

I’m looking for a

    2420 results match your criteria Cutaneous B-Cell Lymphoma

    1 OF 49

    Primary Cutaneous B-Cell Lymphoblastic Lymphoma Arising from a Long-Standing Lesion in a Child and Review of the Literature.
    Pediatr Dermatol 2017 May 26. Epub 2017 May 26.
    Dermatology Program, Boston Children's Hospital, Boston, Massachusetts.
    Precursor B-cell lymphoblastic lymphoma (B-LBL) is a rare entity and primary cutaneous B-LBL is an even more uncommon diagnosis that typically affects children. A 4-year-old boy presented with a persistent rash on his left cheek for almost 2 years and was found to have primary cutaneous B-LBL. We report this case to emphasize that B-LBL should be in the differential diagnosis for an otherwise unimpressive persistent lesion in the head and neck region and review all reported pediatric cases of primary cutaneous B-LBL without extracutaneous involvement. Read More

    Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases.
    J Eur Acad Dermatol Venereol 2017 May 23. Epub 2017 May 23.
    Dermatology, AP-HP, Henri Mondor hospital, Créteil.
    Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is an aggressive primary cutaneous B-cell lymphoma affecting older people.(1) Rituximab (RTX) combined with polychemotherapy (RTX-PCT) has improved survival but relapses are frequent.(2) Central nervous system (CNS) involvement is rare and poorly described. Read More

    Detection of p53 and Bcl-2 expression in cutaneous hemangioma through the quantum dot technique.
    Oncol Lett 2017 May 13;13(5):2937-2944. Epub 2017 Mar 13.
    Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
    Hemangioma is one of the most common types of infantile vascular benign tumor. The aim of the present study was to investigate the role of B-cell lymphoma 2 (Bcl-2) and tumor protein p53 (p53) in the proliferation and apoptosis of hemangioma cells. A total of 38 paraffin-embedded hemangioma specimens (16 males and 22 females) and another 5 paraffin-embedded healthy surrounding tissue samples, collected between January 2007 and December 2010, were obtained from the Department of Pathology at Renmin Hospital of Wuhan University (Wuhan, China). Read More

    Concomitant B Hairy Cell Leukemia and Mycosis Fungoides in an Elderly Man.
    Case Rep Dermatol 2017 Jan-Apr;9(1):103-107. Epub 2017 Apr 7.
    aDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
    The development of both a T- and B-cell lymphoproliferative disorder in one patient is an unlikely coincidence due to the low prevalence of each malignancy. We report a 65-year-old man with a previously documented history of B hairy cell leukemia, who presented with a new-onset acneiform eruption of his scalp, face, trunk, back, and extremities. Routine pathology of the skin lesions with immunohistochemical stains and molecular studies were consistent with a folliculotropic mycosis fungoides. Read More

    Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
    Am J Surg Pathol 2017 May 12. Epub 2017 May 12.
    *Department of Dermatology, HELIOS-Klinikum Hildesheim, Hildesheim †Kempf und Pfaltz, Histologische Diagnostik §Department of Dermatology, Venereology and Allergology, Lower Saxony Institute of Occupational Dermatology, University Medical Center Göttingen, Göttingen, Germany Departments of ‡Psychiatry and Psychotherapy ¶Dermatology, University Hospital Zürich, Zürich, Switzerland.
    Programmed death ligand 1 (PD-L1) is expressed by 20% to 57% of systemic diffuse large B cell lymphomas (DLBCLs). PD-L1 expression in primary cutaneous DLBCL (pcDLBCL) has not been studied so far. Sixteen paraffin-embedded tissue samples of pcDLBCL (13 leg type [LT], 3 others [OT]) were investigated for PD-1, PD-L1, and CD33 expression and the cellular composition of the tumor microenvironment, focusing on myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages. Read More

    Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg-type by massive parallel sequencing.
    J Invest Dermatol 2017 May 4. Epub 2017 May 4.
    Department of Hematology, Henri Becquerel Comprehensive Cancer Center and Normandie Univ, UNIROUEN, Inserm U1245, Team "Genomics and biomarkers in lymphoma and solid tumors", Rouen, France. Electronic address:
    To determine whether the mutational profile of primary cutaneous diffuse large B-cell lymphoma leg-type (PCLBCL-LT) is unique by comparison with other diffuse large B-cell lymphoma (DLBCL) subtypes, we analyzed a total cohort of 28 PCLBCL-LT cases by next generation sequencing with a Lymphopanel designed for DLBCL. We also analyzed 12 pairs of tumor and control DNA samples by whole exome sequencing which led us to perform resequencing of three selected genes not included in the Lymphopanel: TBL1XR1, KLHL6 and IKZF3. Our study clearly identifies an original mutational landscape of PCLBCL-LT with a very restricted set of highly recurrent mutations (>40%) involving MYD88 (p. Read More

    B Cell Lymphoma Underlying Paraffinoma of Glabella.
    J Craniofac Surg 2017 May;28(3):798-800
    *Department of Plastic and Reconstructive Surgery †Department of Pathology, Haeundae Paik Hospital, College of Medicine, The Inje University, Busan, Republic of Korea.
    Soft tissue reactions to paraffin include inflammation, fibrosis, disfigurement, and granulomatous inflammation with foreign body giant cell reaction. The authors report the case of a 77-year-old woman with cutaneous marginal zone B cell lymphoma located on glabella, arising in association with underlying paraffinoma. While it is unclear whether the implant directly contributed to the development of lymphoma, this association has not been previously documented, prompting this report. Read More

    Intravascular Large B Cell Lymphoma Presenting as Fever of Unknown Origin and Diagnosed by Random Skin Biopsies: A Case Report and Literature Review.
    Am J Case Rep 2017 May 2;18:482-486. Epub 2017 May 2.
    Department of Pathology, Hospital de Clinicas "Jose de San Martin", University of Buenos Aires, Buenos Aires, Argentina.
    BACKGROUND Intravascular lymphoma (IVL) is a rare lymphoproliferative disorder characterized by the proliferation of large B lymphoma cells within the lumen of small-caliber blood vessels. Clinical features are nonspecific, presenting as a systemic disease with fever and may be life-threatening. Antemortem diagnosis is difficult but may be made with biopsies of affected tissues or with random skin biopsies. Read More

    Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
    J Clin Oncol 2017 May 1:JCO2016712083. Epub 2017 May 1.
    Camille Laurent, Nadia Amara, Georges Delsol, and Pierre Brousset, Institut Universitaire du Cancer-Oncopole de Toulouse; Centre Hospitalier Universitaire (CHU) Toulouse; Camille Laurent, Georges Delsol, and Pierre Brousset, Institut National de la Santé et de la Recherche Médicale (INSERM), U.1037, Centre de Recherche en Cancerologie de Toulouse-Purpan, Laboratoire d'Excellence Toulouse Cancer; Thomas Filleron, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse, Toulouse; Marine Baron, Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri Mondor-Albert Chenevier; Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, INSERM U955, Université Paris-Est, Créteil; Mylène Dandoit, Marc Maynadié, and Laurent Martin, CHU de Dijon, Dijon; Marie Parrens, Beatrice Vergier, and Antoine de Mascarel, Hôpital du Haut Lévêque, CHU de Bordeaux, Bordeaux; Bettina Fabiani, AP-HP, Hôpital Saint-Antoine; Nicole Brousse and Thierry Jo Molina, AP-HP, Hôpital Necker; Josette Brière, AP-HP, Hôpital Saint Louis; Fréderic Charlotte, AP-HP, Hôpital Pitié Salpétrière; Diane Damotte, AP-HP, Hôpitaux Universitaires Paris Centre, Paris; Alexandra Traverse-Glehen and Françoise Berger, CHU Lyon-Sud; Catherine Chassagne-Clement, Centre Léon Bérard, Lyon; Marie-Christine Copin, Univ Lille, CHU Lille, Lille; Patrick Tas, CHU de Rennes, Rennes; Marie-Christine Rousselet, CHU d'Angers, Angers; Thérèse Rousset, Hôpital Gui de Chauliac, CHU de Montpellier, Montpellier; Luc Xerri, Aix-Marseille Univ, Institut Paoli-Calmettes, Marseille; Anne Moreau and Céline Bossard, Hôpital Hôtel Dieu, CHU de Nantes, Nantes; Antoine Martin, Hôpital Avicenne, Bobigny, Bobigny; Peggy Dartigues, Institut Gustave Roussy, Villejuif; Isabelle Soubeyran, Institut Bergonié, Bordeaux; Michel Peoch, CHU de Saint Etienne, Saint Etienne; Pierre Dechelotte, CHU de Clermont-Ferrand, Clermont-Ferrand; Jean-François Michiels, CHU de Nice, Nice; Flavie Arbion, CHU de Tours, Tours; Isabelle Quintin-Roué, CHU de Brest, Brest; Jean-Michel Picquenot, Centre Henri Becquerel, CHU de Rouen, Rouen; Martine Patey, CHU de Reims, Reims; Blandine Fabre, CHU de Grenoble, Grenoble; Henri Sevestre, CHU d'Amiens, Amiens; Cécile Le Naoures, CHU de Caen, Caen; Marie-Pierre Chenard-Neu, CHU de Strasbourg, Strasbourg; Claire Bastien, CHU de Nancy, Nancy; Sylvie Thiebault, CH de Mulhouse, Mulhouse; Manuela Delage, CHU de Limoges, Limoges; Gilles Salles, Hospices Civils de Lyon, CHU Lyon-Sud; Gilles Salles, INSERM1052, Centre National de la Recherche Scientifique 5286, Université Claude Bernard, Pierre Bénite, France; Tony Petrella, Pathology University of Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Canada.
    Purpose To prospectively assess the clinical impact of expert review of lymphoma diagnosis in France. Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the Lymphopath Network. Changes in diagnosis between referral and expert review were classified as major or minor according to their potential impact on patient care. Read More

    Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    J Clin Oncol 2017 Apr 20:JCO2017726984. Epub 2017 Apr 20.
    Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.
    Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction. Read More

    A Literature Revision in Primary Cutaneous B-cell Lymphoma.
    Indian J Dermatol 2017 Mar-Apr;62(2):146-157
    Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
    The term "Primary Cutaneous B-Cell Lymphoma" (PCBCL) comprehends a variety of lymphoproliferative disorders characterized by a clonal proliferation of B-cells primarily involving the skin. The absence of evident extra-cutaneous disease must be confirmed after six-month follow-up in order to exclude a nodal non-Hodgkin's lymphoma (NHL) with secondary cutaneous involvement, which may have a completely different clinical behavior and prognosis. In this article, we have summarized the clinico-pathological features of main types of PCBCL and we outline the guidelines for management based on a review of the available literature. Read More

    Renaissance of Low-Dose Radiotherapy Concepts for Cutaneous Lymphomas.
    Oncol Res Treat 2017 6;40(5):255-260. Epub 2017 Apr 6.
    Primary cutaneous B- and T-cell lymphomas are rare types of non-Hodgkin's lymphoma with a unique presentation. This can make it challenging for clinicians to manage these cases, and quite often the management mirrors that of other commonly seen lymphomas. This document summarizes how to manage primary cutaneous lymphoma with specific focus on the role of ultralow-dose radiation. Read More

    Erythema ab igne: new technology rebounding upon its users?
    Int J Dermatol 2017 Mar 30. Epub 2017 Mar 30.
    Dermatology and Pathology, Rutgers New Jersey Medical School, Rutgers University School of Public Affairs and Administration, Newark, NJ, USA.
    Erythema ab igne (EAI) is a persistent, chronic skin condition resulting from prolonged exposure to infrared radiation, experienced as heat. Once associated with traditional warming sources like wood burning stoves or open fires, modern, infrared exposure originates also from newer sources like laptops and heating pads and may be creating a rebound of EAI. The epidemiology may be different too, with younger patients than previously seen. Read More

    Nationwide Statistical Analysis of Lymphoid Malignancies in Korea.
    Cancer Res Treat 2017 Mar 30. Epub 2017 Mar 30.
    Cancer Registration and Statistics branch, National Cancer Center, Goyang, Korea.
    Purpose: Regional differences in the incidence of lymphoid malignancies have been reported worldwide, but there has been no large-scale epidemiologic analysis in Korea. The aim of this study was to provide a nationwide population-based statistical analysis of Korean patients with lymphoid malignancies.

    Materials And Methods: The Korea Central Cancer Registry analyzed the incidence and survival of patients with lymphoid malignancies from the Korean National Cancer Incidence Database. Read More

    Chronic lymphocytic leukemia skin infiltration mimicking an ICD pocket infection: a case report.
    BMC Cardiovasc Disord 2017 Mar 24;17(1):89. Epub 2017 Mar 24.
    Department of Hematology, Ceske Budejovice Hospital, Ceske Budejovice, Czech Republic.
    Background: We are presenting a case report on an unreported and unusual cutaneous manifestation of chronic lymphocytic leukemia in a patient with an implantable cardioverter-defibrillator (ICD).

    Case Presentation: A 65-year-old man with a history of chronic lymphocytic leukemia (CLL), previously treated with chlorambucil, was referred in October 2013 for extraction of a single chamber ICD due to a suspected device-related infection in the pulse generator area (left-hand side of Fig. 1). Read More

    Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema.
    J Cutan Pathol 2017 Mar 23. Epub 2017 Mar 23.
    Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
    Chronic lymphedema predisposes to develop malignant cutaneous tumors, including angiosarcoma, Kaposi's sarcoma and B-cell lymphoma. T-cell malignancy has rarely been associated with chronic lymph stasis. Here, we report a case of primary cutaneous anaplastic large cell lymphoma (pcALCL) with lymphatic spread associated with chronic lymphedema. Read More

    Primary cutaneous spindle cell B cell lymphoma: A report of three cases and review of the literature.
    Ann Diagn Pathol 2017 Apr 23;27:18-23. Epub 2016 Nov 23.
    Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
    Primary cutaneous spindle cell lymphoma is a rare variant of primary cutaneous B-cell lymphoma (PCBCL). Herein, we present 3 cases of primary cutaneous spindle cell B cell lymphoma, 2 males and one female (age range 66-76years). The patients presented with solitary skin lesions, distributed in the head and neck area and chest. Read More

    Diffuse large B-Cell lymphoma developing in erythrodermic cutaneous T-cell lymphoma: a case series.
    Br J Dermatol 2017 Mar 16. Epub 2017 Mar 16.
    St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
    Mycosis fungoides (MF) and its leukemic form, Sezary Syndrome (SS), are the most common forms of cutaneous T-cell lymphoma (CTCL). CTCL is associated with an increased risk of secondary cancers, including lymphomas.(1) Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL) in the western world and can involve both nodal and extranodal sites including the skin. Read More

    Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma.
    J Clin Oncol 2017 Mar 13;35(9):955-962. Epub 2017 Feb 13.
    Andrea B. Moffitt and Sandeep S. Dave, Duke University, Durham, NC.
    In this review, we examine the genomic landscapes of lymphomas that arise from B, T, and natural killer cells. Lymphomas represent a striking spectrum of clinical behaviors. Although some lymphomas are curable with standard therapy, the majority of the affected patients succumb to their disease. Read More

    A 92-year-old man with primary cutaneous diffuse large B-cell non-Hodgkin's lymphoma manifesting as a giant scalp mass: A case report.
    Medicine (Baltimore) 2017 Mar;96(10):e6270
    Department of Neurosurgery, XinHua Hospital affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, P.R. China.
    Rationale: Primary cutaneous non-Hodgkin's lymphoma (NHL) is an uncommon entity, representing 10% of all extranodal NHLs. Among all cutaneous sites, the scalp is a rare site of representation.

    Patient Concerns: A 92-year-old Chinese man visited our hospital with a multiple-nodular huge scalp mass on the right parieto-occipital regions. Read More

    Primary cutaneous diffuse large B cell lymphoma-other successfully treated by the combination of R-CHOP chemotherapy and surgery: A case report and review of literature.
    Medicine (Baltimore) 2017 Feb;96(8):e6161
    aDepartment of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, School of Medicine bDepartment of Pathology, Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Xi'an Jiaotong University, School of Medicine, Xi'an, China.
    Rationale: The occurrence of primary cutaneous diffuse large B cell lymphoma-other (PCDLBCL-O) has been rarely reported in the literature. Its diagnosis is based on histopathological and immunohistochemical examinations. To improve the clinical diagnosis and treatment for PCDLBCL-O, we report a case of PCDLBCL-O successfully treated by the combination of R-CHOP (A chemotherapy protocol consists of cyclophosphamide, doxorubicin, vincristine, prednisone plus Rituximab) chemotherapy and surgery. Read More

    A Rare Case of CK20/CK7 Double Negative Merkel Cell Carcinoma.
    Am J Dermatopathol 2017 Mar;39(3):208-211
    *Department of Pathology, University of California Los Angeles, Los Angeles, CA; †Southern California Permanente Medical Group, Department of Dermatology, Sunset Medical Center, Los Angeles, CA; and ‡Department of Pathology, Kaiser Southern California Permanente Medical Group, Los Angeles, CA.
    The authors present a case of Merkel cell carcinoma (MCC) with unique immunohistochemical staining characteristics. A 57-year-old woman presented with a firm 0.3 cm tan papule on her left nasal-labial fold that was reportedly increasing in size and bleeding. Read More

    Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.
    Tumori 2017 Feb 14. Epub 2017 Feb 14.
    Radiation Oncology Department, Azienda Ospedaliera Spedali Civili di Brescia and Brescia University, Brescia - Italy.
    Purpose: To analyze clinical outcome, local response, survival and toxicity in patients with primary cutaneous lymphoma (PCL) treated with radiotherapy.

    Methods: From 1995 to 2014, 112 patients were treated. B-cell lymphomas (CBCLs; n = 86) and T-cell lymphomas (CTCLs; n = 23) were analyzed separately. Read More

    MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8.
    Cell Tissue Res 2017 May 11;368(2):325-335. Epub 2017 Feb 11.
    Centre for Genomics and Child Health and National Centre for Bowel Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, Whitechapel, E1 2AT, London, UK.
    The miR-29 family is involved in fibrosis in multiple organs, including the intestine where miR-29b facilitates TGF-β-mediated up-regulation of collagen in mucosal fibroblasts from Crohn's disease (CD) patients. Myeloid cell leukemia-1 (MCL-1), a member of the B-cell CLL/Lymphoma 2 (BCL-2) apoptosis family, is involved in liver fibrosis and is targeted by miR-29b via its 3'-UTR in cultured cell lines. We investigate the role of MCL-1 and miR-29b in primary intestinal fibroblasts and tissue from stricturing CD patients. Read More

    Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
    J Dtsch Dermatol Ges 2017 Mar 8;15(3):319-323. Epub 2017 Feb 8.
    Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
    Background And Objectives: Intralesional injection of anti-CD20 antibody (rituximab) has been described as effective therapeutic option for patients with indolent primary cutaneous B-cell lymphoma (PCBL). To date, no parameters that reproducibly predict favorable clinical outcome of this treatment have been identified. The study aims to evaluate the clinical response and adverse effects as well as patients' self-perception of intralesional injection of anti-CD20 antibody for treatment of indolent PCBL compared to other treatment modalities. Read More

    Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports.
    Medicine (Baltimore) 2017 Feb;96(5):e5985
    aDepartment of Hematology-Oncology at Sherbrooke University Hospital Center, CIUSSS Estrie, University of Sherbrooke, Sherbrooke bDepartment of Pathology at Sherbrooke University Hospital Center, CIUSSS Estrie, University of Sherbrooke, Sherbrooke cDepartment of Hematology-Oncology at McGill University Health Centre, CIUSSS Centre-Ouest-de-l'Île-de-Montréal, McGill University, Montreal dDepartment of Pathology at Laval University Hospital Center, CIUSSS Capitale Nationale, University Laval, Quebec eDepartment of Hematology-Oncology at Chicoutimi Hospital, CIUSSS Saguenay-Lac-Saint-Jean, University of Sherbrooke, Chicoutimi fDepartment of Pathology at Montreal University Hospital Center, CIUSSS Est-de-l'Île-de-Montréal, University of Montreal, Montreal gDepartment of Pathology at Charles-Lemoyne Hospital, CIUSSS Montérégie-Centre, University of Sherbrooke, Longueuil hDepartment of Pathology at Cité-de-la-Santé Hospital, CIUSSS Laval, Laval iDepartment of Hematology-Oncology at Montreal University Hospital Center in Trois-Rivières, CIUSSS Mauricie-et-du-Centre-du-Québec, Trois-Rivieres jDepartment of Hematology-Oncology at Maisonneuve-Rosemont Hospital, CIUSSS Est-de-l'Île-de Montréal, University of Montreal, Montreal, Quebec, Canada.
    Introduction: Intravascular large B-cell lymphoma (IVL) is an extremely rare malignancy, mainly studied through European and Asian series. Due to the low incidence of this condition, our understanding of the clinical presentation as well as the management of IVL relies on a limited number of patients.We report the largest North American study to date on IVL with 29 cases from Quebec hospital diagnosed between 1990 and 2016. Read More

    IgG4 Expression in Primary Cutaneous Marginal Zone Lymphoma: A Multicenter Study.
    Appl Immunohistochem Mol Morphol 2017 Feb 1. Epub 2017 Feb 1.
    *Department of Dermatology ‡Harvard Medical School §Department of Pathology, Massachusetts General Hospital, Boston, MA †Kempf and Pfaltz, Histologische Diagnostik, Zürich, Switzerland ∥Dermatopathologie Friedrichshafen, Germany.
    Background: Primary cutaneous marginal zone lymphoma (PCMZL) is the second most common B-cell lymphoma of the skin. A recent study has demonstrated a strikingly high prevalence of immunoglobulin (Ig)G4 expression in PCMZL with plasmacytic differentiation.

    Objective: The objective was to investigate the incidence of IgG4 expression in PCMZL, and its correlation with clinical and immunophenotypic features. Read More

    B Cell Lymphoma Underlying Paraffinoma of Glabella.
    J Craniofac Surg 2017 Jan 30. Epub 2017 Jan 30.
    *Department of Plastic and Reconstructive Surgery †Department of Pathology, Haeundae Paik Hospital, College of Medicine, The Inje University, Busan, Republic of Korea.
    Soft tissue reactions to paraffin include inflammation, fibrosis, disfigurement, and granulomatous inflammation with foreign body giant cell reaction. The authors report the case of a 77-year-old woman with cutaneous marginal zone B cell lymphoma located on glabella, arising in association with underlying paraffinoma. While it is unclear whether the implant directly contributed to the development of lymphoma, this association has not been previously documented, prompting this report. Read More

    Primary Cutaneous Follicular Helper T-cell Lymphoma in a Patient With Neurofibromatosis Type 1: Case Report and Review of the Literature.
    Am J Dermatopathol 2017 Feb;39(2):134-139
    *Sunnybrook Health Science Centre, Division of Dermatology, University of Toronto, Toronto, Ontario; and †University Health Network, Toronto General Hospital, University of Toronto, Department of Pathology, Toronto, Ontario.
    Patients with neurofibromatosis type 1 (NF-1) have a well-known predisposition for certain types of malignancies, including lymphoproliferative disorders. Cutaneous T-cell lymphoma (CTCL) has been reported in patients with NF-1, although it is considered a rare entity in this subset of patients. Cutaneous follicular helper T-cell lymphoma (CTFHCL) is a recently emerged rare subtype of CTCL with peculiar clinical and histopathological features and represents a diagnostic and therapeutic challenge. Read More

    Primary cutaneous diffuse large B-cell lymphoma presenting as chronic non-healing ulcer.
    Int Wound J 2017 Jan 24. Epub 2017 Jan 24.
    Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, FL, USA.
    Primary cutaneous diffuse large B-cell lymphoma is an uncommon and aggressive lymphoproliferative disorder with a rapid growth rate and dismal prognosis. We present the case of a 91-year-old female with an unusual manifestation of primary cutaneous diffuse large B-cell lymphoma, mimicking other more prevalent diseases like chronic non-healing venous ulceration. Dermatopathologic evaluation rendered the correct diagnosis. Read More

    Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union.
    Orphanet J Rare Dis 2017 Jan 21;12(1):17. Epub 2017 Jan 21.
    Universidade de Lisboa, Faculdade de Farmácia, Avenida Professor Gama Pinto, 1649-003, Lisboa, Portugal.
    The Committee for Orphan Medicinal Products (COMP) evaluates prevalence of rare conditions as one of the criteria for granting an orphan designation with a prevalence threshold of 5 in 10.000. At the time of Marketing Authorisation (MA) these criteria are reassessed to ensure they are still met. Read More

    A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Leuk Lymphoma 2017 Jun 19;58(6):1349-1357. Epub 2017 Jan 19.
    a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
    A phase 1 study was conducted to determine the dose-limiting toxicities and maximum-tolerated dose (MTD) for bortezomib followed by romidepsin on days 1, 8, and 15 in patients with relapsed/refractory CLL/SLL or B- or T-cell lymphoma. Eighteen treated patients were evaluable for response. The MTD was 1. Read More

    Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma.
    Semin Diagn Pathol 2017 Jan 2;34(1):85-98. Epub 2016 Dec 2.
    Department of Pathology, University of California San Francisco, USA; Department of Dermatology, University of California San Francisco, USA. Electronic address:
    In this review, we present clinical features and detailed histopathologic, immunologic, and molecular information regarding primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type which together represent two of the three most common types of primary cutaneous B-cell lymphoma recognized in the current WHO classification system.(1,2) Overall, B-cell lymphomas represent 19-27% of primary cutaneous lymphomas in most large European and American studies(3-6) and together, primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type account for approximately 2/3 to ¾ of these cases.(5,7-11) Both subtypes can contain a high content of large B-lymphocytes, although most cases of primary cutaneous follicle center lymphomas exhibit a range in cell size and cytology. Read More

    A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Semin Diagn Pathol 2017 Jan 29;34(1):22-35. Epub 2016 Nov 29.
    Kempf und Pfaltz, Histologische Diagnostik, Zürich, Switzerland; Department of Dermatology, University Hospital Zurich, CH-8091, Zurich, Switzerland. Electronic address:
    Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ T-LPD) represent a spectrum encompassing lymphomatoid papulosis (LyP), primary cutaneous anaplastic large-cell lymphoma (pcALCL) and borderline lesions. They share the expression of CD30 as a common phenotypic marker. They differ however in their clinical presentation, the histological features and clinical course. Read More

    Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.
    J Dtsch Dermatol Ges 2016 Dec;14(12):1207-1224
    Department of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Germany.
    Cutaneous B-cell lymphomas (CBCLs) comprise a group of mature lymphoproliferative B-cell disorders that primarily affect the skin. Characterized by great biological and clinical variability among its various subtypes, CBCLs fundamentally differ from primary nodal or systemic B-cell lymphomas. Given their uncomplicated course and excellent prognosis, lymphoma classifications rank primary cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous follicle center lymphoma (PCFCL) as indolent CBCLs. Read More

    Cutaneous EBV-related lymphoproliferative disorders.
    Semin Diagn Pathol 2017 Jan 7;34(1):60-75. Epub 2016 Dec 7.
    Hematopathology, National Cancer Institute (NCI), Bethesda, MD, USA.
    This article will focus on the cutaneous lymphoproliferative disorders associated with EBV, with an emphasis on the upcoming changes in the revised 4th Edition of the WHO classification of tumors of the hematopoietic system, many of which deal with cutaneous disorders derived from NK-cells or T-cells. Extranodal NK/T-cell lymphoma usually presents in the upper aerodigestive tract, but can involve the skin secondarily. EBV-associated T- and NK-cell lymphoproliferative disorders (LPD) in the pediatric age group include the systemic diseases, chronic active EBV infection (CAEBV) and systemic EBV+ T-cell lymphoma of childhood. Read More

    Cutaneous marginal zone lymphomas.
    Semin Diagn Pathol 2017 Jan 29;34(1):76-84. Epub 2016 Nov 29.
    Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, UPMC-Presbyterian, G-335, 200 Lothrop Street, Pittsburgh, PA 15213. Electronic address:
    Primary cutaneous marginal zone lymphoma (CMZL) is one of the major primary B-cell lymphomas of skin. Two types are recognized: a more common class-chain switched CMZL, and a much less common IgM+ CMZL. The extremely indolent course, together with other features distinct from most other MALT lymphomas, has led some to question whether at least the class-switched cases should be considered an overt lymphoma. Read More

    Past, present and future of cutaneous lymphomas.
    Semin Diagn Pathol 2017 Jan 28;34(1):3-14. Epub 2016 Nov 28.
    Research Unit Dermatopathology, Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, 8036 Graz, Austria. Electronic address:
    Primary cutaneous lymphomas represent a broad group of diseases with different clinical, histopathological, phenotypic, molecular, and prognostic features. All cutaneous lymphomas share the same tropism of neoplastic lymphocytes for the skin, but precise classification is paramount for proper management of the patients. Primary cutaneous lymphomas are classified according to the schemes proposed by the European Organization for Research and Treatment of Cancer (EORTC)-Cutaneous Lymphomas Task Force together with the World Health Organization (WHO) in 2005, and the WHO classification of 2008 with the 2016 update. Read More

    Diffuse Subcutaneous Fat Involvement in a Marginal Zone Lymphoma.
    Clin Nucl Med 2017 Feb;42(2):129-130
    From the *Nuclear Medicine Department, Hospices Civils de Lyon, Lyon; †Equipe Mixte de Recherche 3738, Claude Bernard Lyon 1 University; ‡Hematology Department, Hospices Civils de Lyon, Lyon; and §Faculty of Medicine Lyon Sud, Claude Bernard Lyon 1 University.
    Marginal zone lymphoma (MZL) is usually considered not avid for FDG. We report a case of a 57-year-old man with an MZL suspected for transformation. FDG-PET/CT showed a diffuse atypical involvement of subcutaneous fat, without sign suggestive for a transformation. Read More

    Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
    Expert Rev Hematol 2017 Jan 21;10(1):29-37. Epub 2016 Dec 21.
    a Hematology & Oncology , University of Alabama at Birmingham , Birmingham , AL , USA.
    Introduction: CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma. Areas covered: CD30 testing is essential in diagnosis of classical HL and ALCL, and expression can also be seen in other lymphoma subtypes. Read More

    A Clinicopathological Analysis of Primary Cutaneous Lymphomas: A 6-year Observational Study at a Tertiary Care Center of South India.
    Indian J Dermatol 2016 Nov-Dec;61(6):608-617
    Department of Pathology, Government Medical College, Kozhikode, Kerala, India.
    Background: Little data are available concerning clinical and pathological patterns of cutaneous lymphomas in India.

    Aim: To analyze the clinical and histopathological characteristics of cutaneous lymphomas in Indian patients.

    Materials And Methods: This is a single-center, prospective, observational study carried out from January 1, 2010, to December 31, 2015. Read More

    Lymphoma of the eyelid.
    Surv Ophthalmol 2017 May - Jun;62(3):312-331. Epub 2016 Nov 26.
    Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address:
    Lymphoma of the eyelid constitutes 5% of ocular adnexal lymphoma. In previously published cases, 56% of lymphomas of the eyelid are of B-cell origin and 44% are of T-cell origin. The most frequent B-cell lymphomas are extranodal marginal zone lymphoma (27 cases-14%) and diffuse large B-cell lymphoma (18 cases-9%). Read More

    Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
    Leukemia 2016 Dec 16. Epub 2016 Dec 16.
    Division of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
    Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we show that trichostatin A, romidepsin and panobinostat induce apoptosis across a panel of malignant B cell lines, including lines that are intrinsically resistant to bortezomib, etoposide, cytarabine and BH3 mimetics. Read More

    MYD88 mutations in a distinct type of cutaneous marginal zone lymphoma with a non-class switched IgM-immunophenotype.
    Br J Dermatol 2016 Nov 18. Epub 2016 Nov 18.
    Institute of Pathology, Comprehensive Cancer Center, University of Wuerzburg, Germany.
    Somatic mutations in the MYD88 gene are involved in the molecular pathogenesis of different subtypes of Non-Hodgkin B-cell lymphomas such as diffuse large B-cell lymphoma, lymphoplasmacytic lymphoma and Waldenstrom's macroglobulinemia(1) . Albeit with much lower frequency, the key driver mutation MYD88 (c.794T>C, p. Read More

    Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.
    Dis Markers 2016 16;2016:9602472. Epub 2016 Oct 16.
    Dermatology Research Laboratory, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania; Department of Dermatology, Carol Medical Center, 020915 Bucharest, Romania.
    Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive. Read More

    1 OF 49